机译:Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity
Pediatric Oncology Branch, Center for Cancer research, National Cancer Institute;
Division of Oncology, Children’s Hospital of Philadelphia;
Center for Cancer and Blood Disorders, Children’s National HospitalCincinnati Children’s Hospital Medical CenterDepartment of Neurology, Johns Hopkins UniversityRehabilitation Medicine Department, NIH Clinical CenterBiostatistics and Data Management Section, Center for Cancer Research, National Cancer InstituteCancer Therapy Evaluation Program, National Cancer Institute;
MEK inhibitor; neurofibromatosis type 1; patient-reported outcome measures; plexiform neurofibroma; selumetinib;